Akari Therapeutics
AKTX
6 hedge funds and large institutions have $326K invested in Akari Therapeutics in 2024 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
63% less capital invested
Capital invested by funds: $892K → $326K (-$565K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$279K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$22 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OFW
1
Omnia Family Wealth
Aventura,
Florida
| $163K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $90.4K | -$279K | -2,889 | -70% |
|
3
Cerity Partners
New York
| $44.1K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $28K | +$10.8K | +112 | +44% |
|
5
Bank of America
Charlotte,
North Carolina
| $280 | – | – | – |
|
|
TC
6
Truvestments Capital
Sarasota,
Florida
| $93 | – | – | – |
|
7
Morgan Stanley
New York
| $11 | – | – | – |
|
|
CPG
8
Cornerstone Planning Group
Fairfield,
New Jersey
| $7 | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$22 | – | – |
|
AKTX Hedge Fund Activity: Q1 2024 in Review
6 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q1 2024, worth a combined $326K — down 63% from $892K a quarter earlier.
Fund positioning in AKTX was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $10.8K. The largest seller was Sabby Management, cutting an estimated $279K.
- 6 institutional investors held Akari Therapeutics (AKTX) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $326K of Akari Therapeutics stock for Q1 2024, down 63% quarter-over-quarter.
- 0 funds opened new Akari Therapeutics positions in Q1 2024 and 0 closed out.
- The largest Akari Therapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $10.8K added.
- The largest Akari Therapeutics seller in Q1 2024 was Sabby Management, an estimated $279K sold.
Based on aggregated 13F filings for Q1 2024.